In this randomized, placebo-controlled, double-blind study in patients with T2D and prevalent ASCVD or high CV risk, resembling the populations studied in CVOTs with SGLT2 inhibitors, empagliflozin had no significant effect on hemodynamic parameters including systemic vascular resistance index, cardiac index, stroke volume indexor pulse rate after 1 or 3 days of treatment nor after 3 months. Here, SLC5A2 is linked to atherosclerosis.